Payment overview · 2025
General Payments
$660.58
26 reported records · 6 companies
Healthcare provider profile · identity verified
Gregory Grant, MD
Allopathic & Osteopathic Physicians|Family Medicine · SHAWNEE, OK · NPI 1609918234
Verified facts
What the public records show
CMS Open Payments records show Gregory Grant, MD received $660.58 in general payments during 2025 across 26 reported records.
AstraZeneca Pharmaceuticals LP accounted for 40.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $267.37 | 40.5% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $265.76 | 40.2% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.55 | 8.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.64 | 5.5% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $19.97 | 3.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.29 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $660.58 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $247.41 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $227.20 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $58.23 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.55 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $52.55 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $45.70 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $38.56 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.64 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.64 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 73 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 162 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
73 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
162 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
136 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 731 | 216 |
| Gabapentin | Gabapentin | 464 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 383 | 106 |
| Omeprazole | Omeprazole | 371 | 109 |
| Atorvastatin Calcium | Atorvastatin Calcium | 300 | 84 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 297 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 263 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 249 | 72 |
| Famotidine | Famotidine | 246 | 73 |
| Lisinopril | Lisinopril | 237 | 68 |
| Losartan Potassium | Losartan Potassium | 203 | 58 |
| Tramadol Hcl | Tramadol Hcl | 198 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 189 | 50 |
| Alprazolam | Alprazolam | 184 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 170 | 54 |
| Ozempic | Semaglutide | 162 | 37 |
| Montelukast Sodium | Montelukast Sodium | 155 | 44 |
| Simvastatin | Simvastatin | 154 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 43 |
| Celecoxib | Celecoxib | 153 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 39 |
| Metformin Hcl Er | Metformin Hcl | 148 | 47 |
| Potassium Chloride | Potassium Chloride | 144 | 48 |
| Allopurinol | Allopurinol | 143 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 140 | 40 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 140 | 44 |
| Carvedilol | Carvedilol | 139 | 37 |
| Pregabalin | Pregabalin | 139 | 36 |
| Eliquis | Apixaban | 136 | 24 |
| Furosemide | Furosemide | 132 | 46 |
| Meloxicam | Meloxicam | 129 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 127 | 27 |
| Spironolactone | Spironolactone | 122 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 32 |
| Trazodone Hcl | Trazodone Hcl | 108 | 35 |
| Metformin Hcl | Metformin Hcl | 106 | 28 |
| Buprenorphine | Buprenorphine | 104 | 18 |
| Jardiance | Empagliflozin | 102 | 29 |
| Prednisone | Prednisone | 99 | 58 |
| Buspirone Hcl | Buspirone Hcl | 94 | 30 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 85 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 37 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 17 |
| Sertraline Hcl | Sertraline Hcl | 80 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 29 |
| Donepezil Hcl | Donepezil Hcl | 79 | 16 |
| Memantine Hcl | Memantine Hcl | 75 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 75 | 19 |
| Mounjaro | Tirzepatide | 73 | 15 |
| Bupropion Xl | Bupropion Hcl | 72 | 22 |
| Finasteride | Finasteride | 71 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 67 | 23 |
| Glipizide Er | Glipizide | 66 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 21 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 57 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 16 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 56 | 13 |
| Estradiol | Estradiol | 53 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 53 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 16 |
| Myrbetriq | Mirabegron | 50 | 14 |
| Cefdinir | Cefdinir | 48 | 40 |
| Methocarbamol | Methocarbamol | 48 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 47 | 12 |
| Topiramate | Topiramate | 46 | 14 |
| Cephalexin | Cephalexin | 45 | 34 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 18 |
| Trulicity | Dulaglutide | 44 | suppressed |
| Ezetimibe | Ezetimibe | 43 | 13 |
| Torsemide | Torsemide | 43 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 13 |
| Synthroid | Levothyroxine Sodium | 42 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | 11 |
| Chlorthalidone | Chlorthalidone | 41 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 22 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Clonazepam | Clonazepam | 40 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 12 |
| Colestipol Hcl | Colestipol Hcl | 39 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 16 |
| Dutasteride | Dutasteride | 39 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 39 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 38 | suppressed |
| Ibuprofen | Ibuprofen | 37 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Lorazepam | Lorazepam | 35 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 11 |
| Azelastine Hcl | Azelastine Hcl | 33 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 32 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 12 |
| Valsartan | Valsartan | 32 | suppressed |
| Rybelsus | Semaglutide | 31 | suppressed |
| Baclofen | Baclofen | 30 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 26 |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 21 |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | 16 |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Belbuca | Buprenorphine Hcl | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 22 | suppressed |
| Mupirocin | Mupirocin | 21 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 21 | 12 |
| Testosterone Enanthate | Testosterone Enanthate | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 19 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | 11 |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 17 | 13 |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Mesalamine | Mesalamine | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Np Thyroid | Thyroid,pork | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 11 |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | 11 |
| Olanzapine | Olanzapine | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Enbrel | Etanercept | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Sucralfate | Sucralfate | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $660.58 · 26 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, UBRELVY, VRAYLAR, XYOSTED, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error